PHM.MC Stock — Price, Charts & Analysis

Pharma Mar, S.A. (PHM.MC) has a trailing P/E of 25.51x and a forward P/E of 13.13x. This places PHM.MC in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

PHM.MC trades with 25.51x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether PHM.MC looks overvalued or undervalued.

PHM.MC's P/E of 25.51x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

PHM.MC's trailing EPS is €3.22 and forward EPS is €6.26.

EPS, or earnings per share, shows how much profit Pharma Mar, S.A. generated for each share. PHM.MC's trailing EPS is €3.22, and investors usually prefer EPS that is positive and growing over time.

Pharma Mar, S.A. has a market cap of €1.42B, making PHM.MC a small-cap stock based on the current market value shown on Worldtickers.

PHM.MC's latest stock price on Worldtickers is €82.15. The latest move is €0.05 or 0.06%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

PHM.MC's quote includes a latest price of €82.15. The market open is €82.65. Previous close is €82.10. The intraday range is €81.50 to €84.40.

PHM.MC is up in the latest quote, with a move of €0.05 or 0.06%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

PHM.MC generated €218.64M in trailing revenue. Revenue growth is -12.00%, which helps show whether demand is expanding or slowing.

PHM.MC's revenue growth is -12.00%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, PHM.MC shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is €56.13M.

Gross margin is 93.38%. Margins show how efficiently Pharma Mar, S.A. turns revenue into profit.

Pharma Mar, S.A. carries €45.84M and holds €168.88M in cash.

PHM.MC holds €168.88M on its balance sheet.

PHM.MC's book value per share is €14.47.

Yes, Pharma Mar, S.A. pays a dividend of €1.00 per share annually. The dividend yield is 122.00%. The payout ratio is 0.00%.

PHM.MC's dividend yield is 122.00%. Its payout ratio is 0.00%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for PHM.MC. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Pharma Mar, S.A.'s investor relations materials.

Institutions hold 9.65% of PHM.MC shares. Insiders hold 27.21% of shares. Ownership mix helps investors understand how much of Pharma Mar, S.A. is held by professional investors and company insiders.

PHM.MC has 17.32M shares outstanding. Float shares are 13.4M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for PHM.MC, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for PHM.MC is €6.26. Revenue growth is -12.00%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

PHM.MC's trailing EPS is €3.22. Forward EPS is €6.26. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

PHM.MC is in the Healthcare sector. Its earnings multiple is 25.51x. Its latest displayed growth metric is -12.00%. Compare these figures with sector peers before deciding whether Pharma Mar, S.A. is stronger or weaker than average.

PHM.MC trades at €82.15. The stock trades at 25.51x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Pharma Mar, S.A.'s fundamentals.

PHM.MC risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.43, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

PHM.MC should be compared with companies in Biotechnology. Its earnings multiple is 25.51x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Pharma Mar, S.A. (PHM.MC) operates in Healthcare, specifically Biotechnology. Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a

PHM.MC trades on MCE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

PHM.MC stock is priced in EUR on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Pharma Mar, S.A.'s official website listed on Worldtickers is www.pharmamar.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Pharma Mar, S.A. employs about 505 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Pharma Mar, S.A. is headquartered in Madrid, Spain. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

PHM.MC is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

PHM.MC has traded between €64.00 and €105.20 over the past 52 weeks. At €82.15, it is 21.91% below the high and 28.36% above the low. The 52-week range helps gauge long-term price momentum.

PHM.MC is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is €77.02 and its 200-day moving average is €81.48.

PHM.MC's RSI is 55.56. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

PHM.MC's latest RSI reading is 55.56, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for PHM.MC is near €74.85. Key resistance is near €85.40. Breaks above resistance or below support can change the short-term technical setup.

PHM.MC's nearest reported support level is €74.85. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

PHM.MC's nearest reported resistance level is €85.40. A breakout above resistance can improve momentum, especially when volume confirms the move.

PHM.MC trades about 73.43K shares daily on average. The latest displayed volume is 40.75K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

PHM.MC's MACD is 0.37, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

PHM.MC is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 55.56 (neutral). MACD is bullish. Nearest support is around €74.85. Resistance is around €85.40. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is €80.43 (2.08% from price). MA50 is €77.02 (6.59% from price). MA200 is €81.48 (0.76% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. PHM.MC's MA20 is €80.43. MA50 is €77.02. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

PHM.MC's pivot is near €82.52. Support is near €74.85. Resistance is near €85.40. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for PHM.MC is near €77.12. The next upper resistance zone is near €85.72. These levels help define risk and possible follow-through zones after a breakout or breakdown.

PHM.MC's Bollinger range is roughly €76.07 to €84.79. Band width is near 10.84%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

PHM.MC's ATR-based typical daily range is about 2.94%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 40.75K shares. Average volume is about 73.43K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

PHM.MC's all-time high shown on Worldtickers is €323.28. Its all-time low is €10.45. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

PHM.MC has a beta of 0.43, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.